Hydrocortison Vuab

Hydrocortison Vuab is an injectable solution containing the corticosteroid hydrocortisone. The product is supplied without a specified strength and is administered by intramuscular or intravenous injection. It is a prescription‑only medication marketed in the European Union and belongs to the glucocorticoid therapeutic class. Hydrocortison Vuab is used under medical supervision for conditions that require rapid anti‑inflammatory or immunosuppressive action and may be employed in emergency settings.

Hydrocortison Vuab is indicated for several acute medical conditions where rapid glucocorticoid activity is required. It is commonly prescribed by physicians to manage life‑threatening or severe inflammatory states that do not respond to oral therapy. - Adrenal insufficiency, including Addisonian crisis - Severe allergic reactions such as anaphylaxis - Acute inflammatory disorders, including severe asthma exacerbations - Septic or anaphylactic shock - Autoimmune disorders with rapid flare - Other emergency situations requiring systemic corticosteroid support

Hydrocortison Vuab may cause a range of adverse reactions, from mild and transient to serious and potentially life‑threatening.

Common: - Elevated blood glucose levels, especially in patients with pre‑existing diabetes - Mild electrolyte disturbances such as sodium retention and potassium loss - Local discomfort, tenderness, or redness at the injection site - Small‑volume fluid retention causing peripheral edema - Temporary mood or sleep disturbances, including irritability or insomnia

Serious: - Marked hyperglycemia that may precipitate diabetic ketoacidosis - Severe hypertension or exacerbation of cardiovascular disease - Gastrointestinal ulceration or bleeding, particularly with concurrent NSAID use - Opportunistic infections, including fungal or viral reactivations, due to immunosuppression - Acute adrenal insufficiency if the drug is stopped abruptly after prolonged therapy

When prescribing Hydrocortison Vuab, clinicians should evaluate patient history and monitor for conditions that could be aggravated by systemic corticosteroids. - Assess for uncontrolled diabetes, hypertension, or active infections before initiation - Use the lowest effective dose for the shortest duration necessary - Monitor blood glucose, electrolytes, and blood pressure regularly during therapy - Avoid abrupt discontinuation after prolonged use to prevent adrenal crisis - Caution in patients with peptic ulcer disease or a history of gastrointestinal bleeding - Consider alternative therapy in pregnant or breastfeeding women, as safety data are limited - Evaluate for potential psychiatric effects, especially in patients with mood disorders

Hydrocortison Vuab can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use of potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure - Strong immunosuppressants (e.g., high‑dose cyclosporine) that increase infection risk

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) which may raise the chance of gastrointestinal ulceration - Anticoagulants, as corticosteroids can enhance anticoagulant effects and bleeding risk - Diabetic agents, because corticosteroids may diminish glucose control - Vaccines, particularly live attenuated vaccines, due to reduced immune response